HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zentiva Grows In Italy With Acquisition Of Sanofi OTC Brands

Executive Summary

Zentiva adds the Zerinol and Schoum Solution OTC brands to its Italian portfolio as Sanofi continues to offload non-core consumer health brands to focus on its priority categories.

You may also be interested in...



People On The Move: Appointments At Zentiva, Weleda, Probi

A round-up of the latest appointments in Europe's consumer health industry: Zentiva has named Steffen Saltofte as its CEO; Weleda has promoted Thomas Jorberg to chair its executive board; and Probi has hired Von Carlson as VP of operations. The UK's MHRA has also announced the departure of its chair Stephen Lightfoot.

Sanofi Consumer Healthcare Reaches 'Next Level Of Autonomy'

The integration of core business functions at Sanofi Consumer Healthcare represents the “next level of autonomy” for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. “As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more compelling.” The move came as Sanofi Consumer Healthcare reported a strong end to 2022, with Q4 sales up by 6.6% at constant exchange rates to €1.22bn. 

Sanofi To Divest 60% Of Brands In Consumer Healthcare Overhaul

Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel